<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03326375</url>
  </required_header>
  <id_info>
    <org_study_id>GNH_RT-001</org_study_id>
    <nct_id>NCT03326375</nct_id>
  </id_info>
  <brief_title>Comparison of SBRTand Repeat TACE for HCC</brief_title>
  <acronym>STH</acronym>
  <official_title>Comparison of Stereotactic Body Radiation Therapy (SBRT)and Repeat Transarterial Chemoembolization (TACE) for Hepatocellular Carcinoma (HCC) as a Local Salvage Treatment After Incomplete TACE : A Prospective Randomized Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gangneung Asan Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Soonchunhyang University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Gangneung Asan Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Comparison of Stereotactic Body Radiation Therapy (SBRT) and repeated transarterial
      chemoembolization (TACE) for Hepatocellular Carcinoma (HCC)as a Local Salvage Treatment after
      first incomplete TACE
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of this study is to evaluate the effect of SBRT after first incomplete TACE.

      In HCC patients with incomplete TACE response, repeated TACE did not showed good response. In
      this case, SBRT could have better results than TACE.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2017</start_date>
  <completion_date type="Anticipated">March 2021</completion_date>
  <primary_completion_date type="Anticipated">March 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>open labled</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Local tumor control (efficacy fo SBRT)</measure>
    <time_frame>1 year</time_frame>
    <description>To evaluate the effect of SBRT. Local tumor control is defined as the disappearance of any intraarterial enhancement in all target lesions.
Local tumor control will be measured on triphasic Computerized Tomography (CT) or Magnetic Resonance Imaging (MRI). Patient will be asked to visit their study doctor for follow-up exams and imaging (CT or MRI) every 3 months.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>progression free-survival</measure>
    <time_frame>2 year</time_frame>
    <description>survival from SBRT to recurrence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>2 year</time_frame>
    <description>survival from SBRT to death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiation induced liver disease (RILD)</measure>
    <time_frame>1 year</time_frame>
    <description>Liver toxicities were evaluated using Common Terminology Criteria of Adverse Events (CTCAE).
RILD was defined as elevated liver transaminases more than five times the upper normal limit or a worsening of Child-Pugh (CP) score by 2 within 3 months after SBRT.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>HepatoCellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>SBRT (Stereotatic body radiotherapy)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment of SBRT in HCC patients who have incomplete response after first TACE</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TACE (Transarterial chemoembolization)</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Treatment of repeated TACE in HCC patients who have incomplete response after first TACE</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>SBRT</intervention_name>
    <description>Maximum dose : 60Gray (Gy) Fraction : 2 to 5</description>
    <arm_group_label>SBRT (Stereotatic body radiotherapy)</arm_group_label>
    <other_name>Stereotactic Body Radiation Therapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt;18 years

          -  Eastern cooperative oncology group(ECOG) score 0 to 2

          -  Primary HCC

          -  HCC (single nodule ≤ 7 cm or max 3 nodules ≤ 3 cm)

          -  Child-Turgottei-Pugh A or B

          -  Unresectable lesion or medically contraindicated surgery or a case in which surgery
             was declined.

          -  No evidence of radiologically definable major vascular invasion or extrahepatic
             disease

          -  Previously incomplete TACE with radiologically defined residual disease after first
             TACE

          -  Informed consent

        Exclusion Criteria:

          -  Prior TACE to the target lesion

          -  Contraindication to receiving radiotherapy or TACE

          -  Decompensated liver cirrhosis

          -  Extrahepatic mets

          -  Pregnancy

          -  Patients with other cancers
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gab Jin Cheon, M.D, Ph. D</last_name>
    <role>Study Director</role>
    <affiliation>University of Ulsan College of Medicine, Gangneung Asan Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Baek Gyu Jun, M.D</last_name>
    <phone>+82-10-5764-0712</phone>
    <email>backyou78@hanmail.net</email>
  </overall_contact>
  <location>
    <facility>
      <name>Gangneung Asan Hospital</name>
      <address>
        <city>Wŏnju</city>
        <state>Gangwondo</state>
        <zip>25440</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Baek Gyu Jun, M.D</last_name>
      <phone>82-10-5674-0712</phone>
      <email>backyou78@hanmail.net</email>
    </contact>
    <contact_backup>
      <last_name>Gan Jin Cheon, M.D Ph.D.</last_name>
      <phone>82-33-610-3018</phone>
      <email>1000@gnah.co.kr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 24, 2017</study_first_submitted>
  <study_first_submitted_qc>October 25, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 31, 2017</study_first_posted>
  <last_update_submitted>October 25, 2017</last_update_submitted>
  <last_update_submitted_qc>October 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 31, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>TACE</keyword>
  <keyword>SBRT</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

